Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study

Jamila Alessandra Perini, Thais Angeli-Gamba, Jessica Alessandra-Perini, Luiz Claudio Ferreira, Luiz Eurico Nasciutti and Daniel Escorsim Machado

Abstract

Background: Dermal wound healing involves a cascade of complex events including angiogenesis and extracellular matrix remodeling. Several groups have focused in the study of the skin wound healing activity of natural products. The phytomedicine Acheflan®, and its main active constituent is the oil from Cordia verbenacea which has known anti-inflammatory, analgesic and antimicrobial activities. To our knowledge, no investigation has evaluated the effect of Acheflan® in an experimental model of skin wound healing. The present study has explored the wound healing property of Acheflan® and has compared it with topical effectiveness of collagenase and fibrinolysin by using Wistar rat cutaneous excision wound model.

Methods: Animals were divided into four groups: untreated animals are negative control (NC), wounds were treated topically every day with Collagenase ointment (TC), with Fibrinolysin ointment (TF) and with cream Acheflan (TAc). Skin samples were collected on zero, 8th and 15th days after wounding. The healing was assessed by hematoxylin-eosin (HE), picrosirius red, hydroxyproline content and immunohistochemical analysis of the vascular endothelial growth factor (VEGF) and matrix metolloprotease-9 (MMP-9). Statistical analysis was done by ANOVA and Student t-test (p<0.05).

Results: The histological analysis HE of wound in the TAc group was more efficient because it was possible to observe the complete remodeling of the epidermis indicating the regression of lesions compared with the NC. The evaluation of picrosirius staining has demonstrated a significant increase of collagen distribution in the TC and TAc treatments compared with NC and TF groups. These results are corroborated with hydroxyproline content. Skin TC and TAc treated rats have showed an increase of VEGF and MMP-9 compared with NC and TF groups. All parameters were significant (P<0.05).

Conclusion: The phytomedicine Acheflan® (oil of Cordia verbenacea) and TC possess higher therapeutic properties for wound healing compared with TF. These ointments seem to accelerate wound healing, probably due to their involvement with the increase of angiogenesis and dermal remodeling.

Keywords: Acheflan®, Cordia verbenacea, Wound healing, Skin, Collagen, VEGF
Background
Dermal wound healing is a physiological process involving several overlapping stages that could include inflammation, formation of granulation tissue, reepithelialization, extracellular matrix (ECM) formation and remodeling. Loss of skin integrity through trauma, injury and chronic ulcerations may result in homeostasis imbalance and in significant failure [1]. Wounds are major concerns for the medical staff and seriously reduce the quality of life of the patient. Furthermore, skin wound is a public health problem with high cost and ineffective treatment [2]. Thus, the attempt to quickly close the skin lesions with ideal functional and aesthetic results would be the goal of clinical treatment [3].

Nowadays, there has been extensive scientific interest in pharmacological evaluation on the biological properties of phytotherapeutics products [4, 5]. In addition, several studies have focused in evaluating the wound healing activity of medicinal plants, such as Cleome viscosa [6], Crotalus adamanteus [7], Blumea balsamifera [8], Salvia miltiorrhiza [9], Bacopa monniera [10], Vitis Vinifera [11] and Morinda citrifolia [12]. Using an excision wound model in rat, Nayak and colleagues described that extract of Punica granatum promotes faster wound healing from hydroxyproline analysis and histological studies [13]. In this way, experimental models have been developed and have significant improved our knowledge of wound repair because they can be easily accessed to test the efficacy of different treatments [14, 15].

Cordia verbenacea is a Brazilian plant used to producing a phytomedicine, which is the main active constituent of the product Acheflan* developed in Brazil and approved by ANVISA (Agência Nacional de Vigilância Sanitária) in 2004 for the management of trauma, tendinopathy and myofacial pain [4]. In Brazil, the companies need to prove the safety efficacy, quality and safety based on scientific information of phytomedicines because they are registered as drugs [16]. Previous phytochemical study performed with C. verbenacea had demonstrated the main constituents of the essential oil identified by gas chromatography/mass spectrometry (GC-MS) (30 % of α-pinene, 25 % of trans-caryophyllene, 10 % of aloromadendrene and 5 % of α-humulene) [17]. In addition, Chaves and colleagues [18] quantified by GC-MS the main active constituent isolated from Acheflan*, the α-humulene, and 30 min after topical administration of Acheflan*, the amount of α-humulene absorbed in the ear of the mice was about 2 μg/ear. Furthermore, it has been previously reported that the C. verbenacea has anti-inflammatory, analgesic and antimicrobial activity [18–24] and low toxicity [19].

To our knowledge, no investigation has evaluated the effect of Acheflan* in skin injury and our hypothesis was that its use may accelerate the stages of wound healing process. Thus, the purpose of this in vivo study was to evaluate topical effectiveness of Acheflan* on tissue formation, reepithelialization, angiogenesis and, collagen deposition under cutaneous injury and compared with traditional agents (collagenase and fibrinolysin).

Methods
Experimental animal model
Sprague–Dawley rats were used in the accomplishment of the full-thickness excisional wound model using the method described by [25]. 8 weeks old animals and each weighing 250–300 g were housed individually in individual polyethylene cages, and were kept at a constant temperature (25 °C) under a 12-h light/dark cycle with free access to food and water in the Bioterium of Universidade Estadual da Zona Oeste – UEZO (Rio de Janeiro, Brazil). The experimental procedure was approved by the UEZO Institutional Animal Care and Use Committee (CEUA), protocol code CEUA-UZEO-002/2013, and all experiments were conducted in performed with the ethical guidelines from the CEUA.

After the induction of general anesthesia with intraperitoneal ketamine (90 mg/kg) and xylazine (10 mg/kg), the rats’ dorsal regions were shaved and cleaned with ethanol 70 %. The circular full-thickness excision wound was made with a biopsy punch of 20 mm in diameter. The wound was left undressed to the open environment.

Phytomedicine
Acheflan* is a phytomedicine developed in Brazil approved by the local authority ANVISA, Brazilian FDA-like agency, at 2004. This product is a topical drug for the management of trauma, tendinopathy and myofacial pain developed from the Brazilian medicinal plant Cordia verbenacea DC (Boraginaceae). Acheflan* cream (TAc) containing 0.5 % of C. verbenacea essential oil and 2.5 % of α-humulene provided by Aché Laboratory, Brazil.

Wound model and topical treatment
Immediately after surgical excision the rats were randomly divided into four groups of each six animals: untreated animals are negative control (NC), wounds daily treated topically with Collagenase ointment (TC), wounds daily treated topically with Fibrinolysin (1 U fibrinolysin, 666 U DNase and 10 mg chloramphenicol) ointment (TF) and wounds daily treated topically with phytomedicine cream TAc. The rats were euthanized with overdose of anesthesia at 8 and 15 days after wounding. The skin wound samples were collected in each time point: zero (n = 6), 8 days (n = 3) and 15 days (n = 3). The granulation tissue formed on the injury was excised leaving a 5 mm margin of normal skin for histopathological assessment and determination of hydroxyproline.
Histopathologic analysis
The full thickness wound tissues, including the adjacent skin, were fixed immediately in formalin, paraffin-embedded and cut into 4-μm-thick sections. Part of the sections were stained with Harris hematoxylin and eosin (HE), and examined microscopically by two blinded observers using a 40× objective lens of a light microscope (Nikon, Tokyo, Japan) connected to a digital camera (Coolpix 990; Nikon). To estimate the degrees of wound healing a histological score was used to determine the dermal and epidermal regeneration and granulation tissue formation, as described by Kim and colleagues [26]. Additional sections were stained with Picrosirius red for observation of collagen fibers distribution through the calculation of the percentage of the marked area in reddish-yellow by field by using the Image Pro Plus 4.5.1 (Media Cybernetics, Silver Spring, MD).

Immunohistochemistry and morphometric evaluation
The other paraffin-embedded tissue sections were placed on silane-treated slides, and maintained at room temperature. After dewaxing, the sections were treated with a solution of 3 % H2O2 in 0.01 mol/L phosphate buffer saline (PBS), pH 7.5, to inhibit endogenous peroxidase activity. The slides were then immersed in 10 nmol/L citrate buffer (pH 6.0) and heated in a microwave oven for 5 min to retrieve masked antigens, to reduce nonspecific antibody binding; the sections were then incubated with PBS containing a 10 % solution of normal goat serum and 5 % bovine serum albumin for 30 min. Sections were incubated with the following antibodies: monoclonal antibody against VEGF SC-7269 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100 dilution and polyclonal antibody against MMP-9 SC-6840 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilution. Incubations were carried out overnight and then revealed using LSAB2 Kit HRP, rat (Dako-Cytomation, Carpinteria, CA) with diaminobenzidine (3,3′-diaminobenidine tablets; Sigma, St. Louis, MO) as the chromogen and counterstained with hematoxylin. For each case, negative control slides consisted of sections incubated with antibody vehicle or no immune rabbit or mouse serum. Ten fields of an immunostained section (VEGF and MMP-9) were chosen at random and captured from each specimen. Quantification was assessed on captured highquality images (2048 × 1536 pixels buffer) using the Image Pro Plus 4.5.1 (Media Cybernetics, Silver Spring, MD). Data were stored in Adobe Photoshop, version 3.0, to enable uneven illumination and background color to be corrected. Histologic scores (H) for VEGF and MMP-9 were calculated using the formula H = ΣPi, where i is the intensity ranging from 0 (negative cells) to 3 (deeply staining cells) and P is the percentage of staining cells for each given i, with P values of 1, 2, 3, 4, and 5 indicating <15 %, 15–50 %, 50–85 %, >85 %, and 100 % positive-staining cells, respectively. The staining result was expressed as mean ± standard deviations.

Biochemical analyses of the newly formed skins
The hydroxyproline, the basic constituent of collagen, was taken as a marker of collagen synthesis. The granulation tissue from control and treated groups was dried at 60–70 °C for 24 h and weighed to determine the dry granulation tissue weight. Pieces of dried tissue were hydrolysed in 6 N HCl at 120 °C for 18 h in sealed tubes. The hydrolyzed samples were adjusted to pH 7.0 and were subjected to chloramines-T oxidation for 20 min. The reaction was terminated by addition of 3.15 M perchloric acid and para-dimethylaminobenzaldehyde at 60 °C to develop a pink color [27]. Absorbance was measured at 557 nm using a spectrophotometer. The procedure was done in triplicate for all samples, in each time point (zero, 8 and 15 days) and the hydroxyproline content was determined against a standard curve of hydroxyproline.

Statistical analysis
One-way analysis of variance (ANOVA) was carried out to identify the differences between treated groups and controls. Statistical comparisons between variables were performed with Student t-test. The level of significance for significant difference between groups was set at P <0.05 in all analyses.

Results
Histologic wound scoring was conducted in a blinded fashion using the dermal and epidermal regeneration and the granulation tissue thickness, as described by Kim and colleagues [26]. In both observations, the histological analysis of wound in the treated groups at days 8 and 15 showed that wounds displayed better epithelialization and more effective re-organization of the dermis when compared with the control group (Fig. 1). When compared between the treated groups, the TAc was more efficient because it was possible to observe that the complete remodeling of epidermis indicated the regression of the lesions.

The evaluation of picrosirius staining demonstrated a significant increase of collagen distribution in the TC and TAc treatments compared with NC and TF groups. Already on day 8, it was possible to observe the intense reddish-yellow coloration of the collagen on TC and TAc, indicates that especially these treatments have contributed to the greater synthesis of these fibers (Fig. 2). These observations were confirmed by the percentage of area occupied by collagen fibers in each cut (Table 1). Similar results were shown on biochemical analysis of hydroxyproline levels, the basic constituent of collagen. In the TC and TAc, the hydroxyproline content of dry granulation tissue was significantly higher compared with
NC and TF on day 8 (Table 2). These results suggest that TC and TAc have strong wound healing potential.

The distribution of VEGF, which is one of the most prominent angiogenic markers, was detected focally on the dermis in both control and treated groups (Fig. 3). On day 8, the immunoreactivity was higher again in TC and TAc and it was almost similar in the other groups. On the day 15, the distribution of VEGF was reduced in all treated groups, but in TC and TAc there are less reduction, while a low expression was seen in the NC. The histologic scores of VEGF were statistically higher in TC and TAc, as shown by the morphometry evaluation (Table 1).

The MMP-9 immunodistribution was similar to that of VEGF, but was more intense in TC on day 8 (Fig. 4). At this time, the reactivity of the MMP-9 was very increased in TC, which strong labeling in all the tissue. As observed in the VEGF study, the distribution of MMP-9 was reduced on the day 15, and no differences were observed among the treated groups. Comparing the different groups, MMP-9 histologic scores were higher, particularly in TC on day 8 (Table 1).
Table 1 Histologic scores of collagen fibers, VEGF and MMP-9 in studied groups

| Score (%)       | Group | Day 0   | Day 8   | Day 15  |
|-----------------|-------|---------|---------|---------|
| Collagen fibers | NC    | 60.3 ± 0.9 | 163 ± 1.4 | 59.9 ± 1.6 |
|                 | TC    | 60.3 ± 0.9 | 76 ± 1.2 | 713 ± 1.6 |
|                 | TF    | 60.3 ± 0.9 | 10.9 ± 1.6 | 20.2 ± 1.4 |
|                 | TAc   | 60.3 ± 0.9 | 68.9 ± 1.2 | 67.8 ± 0.8 |
| P value<sup>a</sup> | 1.0 | 0.0001 | 0.0001 |
| VEGF            | NC    | 15.7 ± 0.7 | 19.5 ± 2.1 | 2.6 ± 1.0 |
|                 | TC    | 15.7 ± 0.7 | 28.2 ± 1.5 | 15.5 ± 1.3 |
|                 | TF    | 15.7 ± 0.7 | 18.6 ± 0.8 | 120 ± 1.2 |
|                 | TAc   | 15.7 ± 0.7 | 26.4 ± 1.8 | 173 ± 1.1 |
| P value<sup>a</sup> | 1.0 | 0.0001 | 0.0001 |
| MMP-9           | NC    | 0.9 ± 0.8 | 10.2 ± 0.9 | 8.3 ± 1.1 |
|                 | TC    | 0.9 ± 0.8 | 47.8 ± 1.9 | 10.8 ± 1.9 |
|                 | TF    | 0.9 ± 0.8 | 11.9 ± 1.4 | 10.9 ± 1.7 |
|                 | TAc   | 0.9 ± 0.8 | 17.1 ± 0.8 | 11.4 ± 0.6 |
| P value<sup>a</sup> | 1.0 | 0.0001 | 0.0001 |

NC is negative control, TC is treated topically with Collagenase ointment, TF is treated topically with Fibrinolysin and TAc is treated topically with phytomedicine cream Acheflan. Day zero, 8th and 15th days after injury. Values are mean ± standard deviations. *Anova test. Significant difference when compared to NC group (Student t test, P < 0.05). Significant difference when compared to TF group (Student t test, P < 0.05). Significant difference when compared to TC group (Student t test, P < 0.05)

Discussion

In this study we propose for the first time that Acheflan® possess higher therapeutic properties for wound healing compared with TF and the effect was similar to TC. We have demonstrated a better tissue formation and reepithelialization, an increased distribution of collagen deposition and significantly enhanced angiogenic marker in the cutaneous injuries treated with TC and Acheflan®.

Skin wound healing is a complex physiological process that involves multiple tissue and cell types, and usually the wound progresses toward homeostasis through steps involving inflammation, new tissue formation, and tissue remodeling [28]. However, cutaneous wound healing is a major interest for the public health sector because the skin wounds affect a large number of patients, seriously reducing their quality of life, requiring extended hospitalization time, and accounts for a significant amount of healthcare expenditures. Furthermore, the scientific information about the potential effect of topical agents on skin wound healing is limited [29]. Natural products have consistently been an important source of therapeutic agents, therefore, we have evaluated and compared topical effectiveness of collagenase and fibrinolysin with phytomedicine Acheflan® on cutaneous injury.

Proteolytic enzymes have been used for wound debridement for many years and the two most widely used enzymes in the world are fibrinolysin/DNase and collagenase [30–33]. The collagenases, an enzymatic debriding agent, act by degrading native helical collagen fibrils [34]. Recently, Tallis and colleagues [33] showed that collagenase ointment is tolerable and clinically effective in achieving the removal of nonviable tissue in the preparation of a healthy wound bed. In addition, a study on infected accidental or surgical wounds, debridement using fibrinolysin/DNAse was reportedly effective [35].

The main active constituent from the phytomedicine Acheflan® is the oil from C. verbenacea, and its topical anti-inflammatory and antinociceptive properties have already been reported [18, 20, 23, 24]. Acheflan® was approved by ANVISA in Brazil for the management of tendinopathy, myofacial pain and trauma [4]. As far as we know, the present work is the first study to focus on the effect of Acheflan® in wound-healing model, and we have showed that this phytomedicine had a role in the early wound healing processes. This effect displayed may be attributed to the compounds isolated from C. verbenacea, sesquiterpene α-humulene, which has revealed important anti-inflammatory and antinociceptive properties [18, 20, 23, 24]. In addition, previous data with Acheflan® cream showed that the α-humulene is completely and fast absorbed when applied topically [18].

Collagen has a well-established function in early wound healing, and is the main component which strengthens and supports extra cellular tissue, it is composed of amino acid, hydroxyproline, which has been used as a biochemical marker for tissue collagen [36, 37]. During the proliferative phase, type III collagen is secreted by migrating and proliferating fibroblasts, in and around the wound, and this collagen is essential for creating the provisional matrix during this phase. Type I collagen is also vital during the maturation period and the most prevalent collagen in uninjured skin [38]. Acheflan® has demonstrated a significant increase in the hydroxyproline content and
collagen distribution of the granulation tissue after 8 days of injury indicating increased collagen turnover. Similar results were reported with increase hydroxyproline content around 2 times using excision wound model in rats treated with extract of *Punica granatum* [13], *Vitis vinifera* and *Vaccinium macrocarpon* [39], *Allamanda cathartica* [40], *Ixora coccinea* [41] and *Cleome viscose* [6].

We used the immunohistochemical technique to observe the angiogenesis process through VEGF marking in our experimental model. The VEGF is an angiogenic peptide produced by endothelial cells, macrophages, and many other cells, being an excellent marker for endothelial cells [42]. In the present study, the TC and Acheflan® exhibited the most intense distribution of VEGF in day 8th, indicating that this factor is mainly stimulated in the early period of wound healing. This is in agreement with the findings that many processes are involved in the early period of wound healing and require action of many factors to facilitate cell movement, granulation tissue formation and angiogenesis [43–45].

On the other hand, changes in the ECM associated with disease states may arrest progression of the
sequence of stages, critical for wound healing. Exorbi-
tant production of a collagenous matrix can be also
questionable, resulting in cutaneous scarring that pro-
duce esthetic problem, functional damage, and discom-
fort [46]. In our study there is an interesting difference
between MMP-9 distribution in TC and Acheflan® on
day 8, with distribution in TC group extensively higher.
We know that MMP-9 have important function in the
angiogenesis process in dermal remodeling, but excer-
bated levels seem to be negatively implicated in the
tissue degradation. In the same way, Kurtz and Oh [47]
also demonstrated that the aberrant ECM expression
may provide to pathologic wound responses.

We should consider that human skin differs from rat
skin, and the important difference is that human skin
heals preferentially by re-epithelialisation, while rat skin
heals mainly by wound contraction [14]. We acknowledge
the limitations for translational relevance of our experi-
mental study; however, skin lesions in animal models are
pertinent because provide significant contributions to ad-
vances in the treatment of skin wounds. Despite the limi-
tations of the experimental model, we have showed higher
topical effectiveness of Acheflan® on tissue formation, re-
epithelialization, angiogenesis, collagen deposition under
cutaneous injury compared with TF.

Conclusion
In conclusion, our findings have demonstrated that Ache-
flan® accelerates wound healing in skin rat model, prob-
dably due to its involvement with the increase angiogenesis
and dermal remodeling.

Abbreviations
CEUA: Institutional Animal Care Committee; DNAse: Desoxirribonuclease;
ECM: Extracellular matrix; GC-MS: Gas chromatography/mass spectrometry;
H: Histologic scores; HE: Hematoxylin-eosin; MMP-9: Matrix metalloprotease-9;
NC: Negative control; PBS: Phosphatebuffer saline; TC: Collagenase ointment;
TF: Fibrinolysin ointment; TAc: Cream Acheflan; UEZO: University State of
West Zone; VEGF: Vascular endothelial growth factor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JAP designed the research, analyzed data, wrote the manuscript and
obtained funding. TAG induce experimental wound model and helped to
all experiments. JA helped to all experiments and edited the manuscript.
LCF helped to histopathologic analysis. LEN critical discussion and edited
the manuscript. DEM contributed to the idea, helped to all experiments,
analyzed data and wrote the manuscript. All authors read and approved
the final manuscript.

Acknowledgements
The authors thank Francisco das Chagas Carvalho from Instituto Nacional de
Infectologia Evandro Chagas of Fundação Oswaldo Cruz of Rio de Janeiro,
Brazil, for his technical assistance. This study was supported by the Brazilian
agency Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do
Rio de Janeiro - FAPERJ, Brazil (E-26/110.391/2012 and E-26/100.771/2014).

Author details
1Laboratório de Pesquisa de Ciências Farmacêuticas, Unidade de Farmácia,
Centro Universitário Estadual da Zona Oeste, Av. Manoel Caldeira de
Alvarenga, 1,203, Campo Grande, 23070-200 Rio de Janeiro, RJ, Brazil.
2Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola
Nacional de Saúde Pública, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
3Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro,
Rio de Janeiro, RJ, Brazil.

Received: 18 November 2014 Accepted: 24 June 2015
Published online: 30 June 2015

References
1. Shaw TJ, Martin P. Wound repair at a glance. J Cell Sci. 2009;122:3209–13.
2. Singh A, Halder S, Menon GR, Chumber S, Misra MC, Sharma UK, et al. Meta-
analysis of randomized controlled trials on hydrocolloid occlusive dressings
versus conventional gauze in healing chronic wounds. Asian J Surg.
2004;27:326–32.
3. Singer AJ, Dagum AB. Current management of acute cutaneous wounds.
N Engl J Med. 2008;359:1037–46.
4. Calisto JB. Twenty-five years of research on medicinal plants in Latin America: a
personal view. J Ethnopharmacol. 2005;100:131–7.
5. Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines
a personal view. J Ethnopharmacol. 2005;100:131–7.
6. Upadhyay A, Chattopadhyay P, Goyary D, Mazumder PM, Veer V. Topical
application of Cleome viscosa increases the expression of basic fibroblast
growth factor and type III collagen in rat cutaneous wound. Biomed Res Int.
2014;2014:1–7.
7. Samy RR, Kandasamy M, GOPalakrishnakone P, Stiles BG, Rowan EG, Becker D,
et al. Wound healing activity and mechanisms of action of an antibacterial
protein from the Venom of the Eastern Diamondback Rattlesnake (Crotalus
adamanteus). Plos One. 2014;9(1):–16.
8. Pang Y, Wang D, Fan Z, Chen X, Yu F, Hu X, et al. Blumea balsamifera—a
different chemical and pharmacological review. Molecules. 2014;19:4943–77.
9. Zhang ZR, Li JH, Li S, Liu AL, Hoi PM, Tian HY, et al. In vivo angiogenesis
screening and mechanism of action of novel tanshinone derivatives
produced by one-pot combinatorial modification of natural tanshinone
mixture from Salvia miltiorrhiza. Plos One. 2014;9(1):–15.
10. Munthy S, Gautam MK, Goel S, Purohit V, Sharma H, Goel RK. Evaluation of in
d vivo wound healing activity of Bacopa monniera on different wound model
in rats. Biomed Res Int. 2013;2013:1–9.
11. Nayak SB, Randath DD, Marshall JR, Istor GN, Eversley M, Xue S, et al.
Wound-healing activity of the skin of the common grape (Vitis Vinifera)
variant, Cabernet Sauvignon. Phytother Res. 2010;24:1151–6.
12. Nayak SB, Sandford S, Maxwell A. Evaluation of the wound-healing activity
of ethanolic extract of Morinda citrifolia L. Leaf. Evid Based Complement
Alternat Med. 2009;6:325–31.
13. Nayak SB, Rodrigues V, Mahara S, Bhogadi VS. Wound healing activity of the
fruit skin of Punica granatum. J Med Food. 2013;16:857–63.
14. Wong WW, Sorkin M, Glotzbach JP, Longaker MT, Gurtner GC. Surgical
approaches to create murine models of human wound healing. J Biomed
Biotechnol. 2011;2011:1–8.
15. Dorsett-Martin WA. Rat models of skin wound healing: a review. Wound
Repair Regen. 2004;12:591–9.
16. Calisto JB. Efficacy, safety, quality control, marketing and regulatory guidelines
for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res.
2000;33:179–89.
17. de Carvalho PMJR, Rodrigues RF, Sawaya AC, Marques MO, Shimizu MT.
Chemical composition and antimicrobial activity of the essential oil of
Cordia verbenacea D.C. J Ethnopharmacol. 2004;95:297–303.
18. Chaves JS, Leal PC, Pianowisky L, Calixto JB. Pharmacokinetics and tissue
distribution of the sesquiterpene alpha-humulene in mice. Planta Medica
2000;66:179–85.
19. Seidel JA, Wolsky RG, Weigel G, Rodrigues M. Pharmacological assay of Cordia
verbenacea: oral and topical anti-inflammatory activity, analgesic effect and
fetus toxicity of a crude leaf extract. Phytotherapy 2005;12:384–4.
20. Medeiros R, Passos GF, Vitor CE, Koepp J, Mazzuco TL, Pianowski LF,
Campos MM. Calisto JB. Effect of two active compounds obtained from the
essential oil of Cordia verbenacea on the acute inflammatory responses
elicited by LPS in the rat paw. British Journal of Pharmacology
2007;151:618–27.

Page 7 of 8
21. Matias EFF, Alves EF, Santos BS, Souza CES, Ferreira JVA, Lavor AKLS, et al. Biological activities and chemical characterization of Cordia verbenacea DC. as tool to validate the ethnobiological usage. Evid Based Complement Alternat Med. 2013;2013:1–7.

22. Pimentel SP, Barrella GE, Casarin RCV, Cirano FR. Protective effect of topical Cordia verbenacea in a rat periodontitis model: immune-inflammatory, antibacterial and morphometric assays. BMC Complement Altern Med. 2012;12:224.

23. Passos GF, Fernandes ES, da Cunha FM, Ferreira J, Pianowski LF, Campos MM, et al. Anti-inflammatory and anti-allergic properties of the essential oil and active compounds from Cordia verbenacea. J Ethnopharmacol. 2007;110:323–33.

24. Fernandes ES, Passos GF, Medeiros R, da Cunha FM, Ferreira J, Campos MM, et al. Anti-inflammatory effects of compounds α-humulene and (−)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Eur J Pharmacol. 2007;569:228–36.

25. Morton JJP, Malone MH. Evaluation of vulnerary activity by an open wound procedure in rats. Arch Int Pharmacodyn. 1972;196:117–9.

26. Kim SW, Zhang HZ, Guo L, Kim JM, Kim MH. Amniotic mesenchymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities. Plos One. 2012;7:1–11.

27. Woessner JFJ. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961;99:440–7.

28. Guttenr GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–21.

29. Rizzi SC, Upton Z, Bott K, Dargaville TR. Recent advances in dermal wound healing: biomedical device approaches. Expert Rev Med Devices. 2010;7:143–54.

30. Peter FW, Li-Peuser H, Vogt PM, Muehlberger T, Homann HH, Steinau HU. The effect of wound ointments on tissue microcirculation and leucocyte behaviour. Clin Exp Dermatol. 2002;27:51–5.

31. Marazzi M, Stefan A, Chiaratti A, Orlandini MN, Falcone L, Rapisarda V. Effect of enzymatic debridement with collagenase on acute and chronic hard-to-heal wounds. Journal Wound Care. 2006;15:222–7.

32. Ostlie DJ, Juang D, Aquayo P, Pettiford-Cunningham JP, Erkmann EA, Rash OE, et al. Topical silver sulfadiazine vs collagenase ointment for the treatment of partial thickness burns in children: a prospective randomized trial. J Pediatr Surg. 2012;47:1204–7.

33. Tallis A, Motley TA, Wunderlich RP, Dickerson Jr JE, Waycaster C, Slade HB, et al. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study. Clin Ther. 2013;35:1805–20.

34. Mekkes JR, Zeegelaar JE, Westerhof W. Quantitative and objective evaluation of wound debriding properties of collagenase and fibrolysin/deoxyribonuclease in a necrotic ulcer animal model. Arch Dermatol Res. 1998;290:152–7.

35. Schwarz N. Enzymatic wound debridement with a combination of fibrolysin and deoxyribonuclease. Fortschr Med. 1981;99:78–80.

36. Long KB, Burgwin CM, Huneke R, Artlett CM, Blankenhorn EP. Tight skin 2 mice exhibit delayed wound healing caused by increased elastic fibers in fibrotic skin. Adv Wound Care (New Rochelle). 2014;3:573–81.

37. El-Mesallamy HO, Diab MR, Hamdy NM, Dardir SM. Cell-based regenerative strategies for treatment of diabetic skin wounds, a comparative study between human umbilical cord blood-mononuclear cells and calves’ blood haemodilysate. Plos One. 2014;9(1):10.

38. Broughton 2nd G, Janis JE, Attinger CE. The basic science of wound healing. Plastic Reconstr Surg. 2006;117(7 Suppl):25–945.

39. Nayak SB, Randdath DO, Marshall JR, Istor G, Xue S, Shi J. Wound-healing properties of the oils of Vitis vinifera and Vaccinium macrocarpon. Phytother Res. 2011;25:1201–8.

40. Nayak SB, Nalabothu P, Sandford S, Bhogadi V, Adogwa A. Evaluation of wound healing activity of Allamanda cathartica. J and Laurus nobilis. L. extracts on rats. BMC Complement Altern Med. 2006;6:12.

41. Upadhyay A, Chattopadhyay P, Gayaj D, Mazumder PM, Vee V. Icra cocinea enhances cutaneous wound healing by regulating the expression of collagen and basic fibroblast growth factor. ISRN Pharmacol. 2014;2014:751824.

42. Soyer T, Ayva S, Aliiefendigolu D, Akta Z, Aslan MK, Senyucel MF, et al. Effect of phototherapy on growth factor levels in neonatal rat skin. J Pediatr Surg. 2011;46:2128–31.

43. Martin P. Wound healing—aiming for perfect skin regeneration. Science. 1997;276:75–81.

44. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738–46.

45. Kim CH, Lee JH, Won JH, Cho MK. Early activation of matrix metalloproteinase-9 and vascular endothelial growth factor. J Korean Med Sci. 2011;26:726–33.

46. Volk SW, Kbal SA, Bayat A. Interactions of the extracellular matrix and progenitor cell in cutaneous wound healing. Adv Wound Care. 2013;2:361–72.

47. Kurtz A, Oh SJ. Age related changes of the extracellular matrix and stem cell maintenance. Prev Med. 2012;54:550.